The following content was originallally published by Cell & Gene on March 30, 2023.
The science behind advanced, cell-and-gene-based drugs is developing rapidly, opening new opportunities for targeted, highly effective therapeutics. Around the world, companies are currently researching thousands of these lifesaving drugs. However, manufacturing them on a large scale presents logistical challenges that often result in a slow, costly process.
Unlike chemically based drugs, cell-and-gene therapeutics may require a complex scale-up strategy, progressing from preclinical research to clinical trials and ultimately to commercial manufacturing. These technological challenges can delay the entire drug development process and reduce companies’ return on investment (ROI). However, contract development and manufacturing organizations (CDMOs) are uniquely positioned to solve this problem. As emerging technology influencers, they fill the gap between cutting-edge science and the commercial sector by partnering with the best technology providers to maximize the manufacturing process.